Gamma imaging⇓guided minimally invasive breast biopsy: Initial clinical experience

Document Type

Journal Article

Publication Date



American Journal of Roentgenology








Breast cancer; Breast-specific gamma imaging; Gamma imaging–guided breast biopsy; Minimally invasive biopsy; Molecular breast imaging


© American Roentgen Ray Society. OBJECTIVE. The purpose of this study was to evaluate our initial experience with gamma imaging–guided vacuum-assisted breast biopsy in women with abnormal findings. MATERIALS AND METHODS. A retrospective review of patients undergoing breast-specific gamma imaging (BSGI), also known as molecular breast imaging (MBI), between April 2011 and October 2015 found 117 nonpalpable mammographically and sonographically occult lesions for which gamma imaging–guided biopsies were recommended. Biopsy was performed with a 9-gauge vacuum-assisted device with subsequent placement of a titanium biopsy site marker. Medical records and pathologic findings were evaluated. RESULTS. Of the 117 biopsies recommended, 104 were successful and 13 were canceled. Of the 104 performed biopsies, 32 (30.8%) had abnormal pathologic findings. Of those 32 biopsies, nine (28.1%) found invasive cancers, six (18.8%) found ductal carcinoma in situ (DCIS), and 17 (53.1%) found high-risk lesions. Of the 17 high-risk lesions, there were three (17.6%) lobular carcinomas in situ, five (29.4%) atypical ductal hyperplasias, two (11.8%) atypical lobular hyperplasias, one (5.9%) flat epithelial atypia, and six (35.3%) papillomas. Two cases of atypical ductal hyperplasia were upgraded to DCIS at surgery. The overall cancer detection rate for gamma imaging–guided biopsy was 16.3%. In this study, gamma imaging–guided biopsy had a positive predictive value of total successful biopsies of 16.3% for cancer and 30.8% for cancer and high-risk lesions. CONCLUSION. Gamma imaging–guided biopsy is a viable approach to sampling BSGI-MBI–detected lesions without sonographic or mammographic correlate. Our results compare favorably to those reported for MRI-guided biopsy.

This document is currently not available here.